ReviewJournal of biomedical science2011
Immunomodulatory properties of human adult and fetal multipotent mesenchymal stem cells.
Review in Journal of biomedical science, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04011059 (Randomized Study as Proof of Concept of Coronary Revascularization Surgery With Injection of Wharton's Jelly-derived Mesenchymal Cells and Placement of an Epicardial Extracellular Matrix Patch Seeded With WJ-MSCs in Patients With Ischemic Cardiomyopathy), which is not on this map. Cited by 77 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Randomized Study as Proof of Concept of Coronary Revascularization Surgery With Injection of Wharton's Jelly-derived Mesenchymal Cells and Placement of an Epicardial Extracellular Matrix Patch Seeded With WJ-MSCs in Patients With Ischemic Cardiomyopathy
Who cites it
77 citing papers in PubMed, 178 citations in OpenAlex.
- Trial
- Sustained benefit from combined plasmapheresis and allogeneic mesenchymal stem cells transplantation therapy in systemic sclerosis.Arthritis research & therapy · 2017Trial
- Stem Cells and their Key Derivatives in Degenerative Musculoskeletal Diseases.Stem cell reviews and reports · 2026Review
- Donor age and sex program MSC secretome signaling: a quadrant framework for precision therapy.Stem cell research & therapy · 2026Article
- Turner syndrome: the promise of fertility via stem cell technology.Hormones (Athens, Greece) · 2025Review
- Deep insight into cytokine storm: from pathogenesis to treatment.Signal transduction and targeted therapy · 2025Review
- Human fetal lung mesenchymal stem cells ameliorate lung injury in an animal model.Scientific reports · 2025Article
- Revolutionizing medicine: recent developments and future prospects in stem-cell therapy.International journal of surgery (London, England) · 2024Review
- The role of fetal pancreatic islet cell transplantation in the treatment of type 2 diabetes mellitus.Journal of diabetes and metabolic disorders · 2024Article
- Bone marrow-derived mesenchymal stem cells reduce CClRenal failure · 2024Article
- Stem Cells and Infertility: A Review of Clinical Applications and Legal Frameworks.Journal of personalized medicine · 2024Review
- Anticancer peptides as novel immunomodulatory therapeutic candidates for cancer treatment.Exploration of targeted anti-tumor therapy · 2024Review
- Liver Disease and Cell Therapy: Advances Made and Remaining Challenges.Stem cells (Dayton, Ohio) · 2023Review
- A new era of gene and cell therapy for cancer: a narrative review.Annals of translational medicine · 2023Review
- Human Fetal Cartilage-Derived Progenitor Cells Exhibit Anti-Inflammatory Effect on IL-1β-Mediated Osteoarthritis Phenotypes In Vitro.Tissue engineering and regenerative medicine · 2022Article
- Review
- Advances in mesenchymal stem cell therapy for immune and inflammatory diseases: Use of cell-free products and human pluripotent stem cell-derived mesenchymal stem cells.Stem cells translational medicine · 2021Review
- Review
- Human fetal liver MSCs are more effective than adult bone marrow MSCs for their immunosuppressive, immunomodulatory, and Foxp3Stem cell research & therapy · 2021Article
- Culture density of menstrual blood-derived stromal/stem cells determines the quality of T cell responses: An experimental study.International journal of reproductive biomedicine · 2021Article
17 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In recent years, a large number of studies have contributed to our understanding of the immunomodulatory mechanisms used by multipotent mesenchymal stem cells (MSCs). Initially isolated from the bone marrow (BM), MSCs have been found in many tissues but the strong immunomodulatory properties are best studied in BM MSCs. The immunomodulatory effects of BM MSCs are wide, extending to T lymphocytes and dendritic cells, and are therapeutically useful for treatment of immune-related diseases including graft-versus-host disease as well as possibly autoimmune diseases. However, BM MSCs are very rare cells and require an invasive procedure for procurement. Recently, MSCs have also been found in fetal-stage embryo-proper and extra-embryonic tissues, and these human fetal MSCs (F-MSCs) have a higher proliferative profile, and are capable of multilineage differentiation as well as exert strong immunomodulatory effects. As such, these F-MSCs can be viewed as alternative sources of MSCs. We review here the current understanding of the mechanisms behind the immunomodulatory properties of BM MSCs and F-MSCs. An increase in our understanding of MSC suppressor mechanisms will offer insights for prevalent clinical use of these versatile adult stem cells in the near future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.